ECE2006 Poster Presentations Neuroendocrinology and behaviour (70 abstracts)
Hopital de Bologhine, Algiers, Algeria.
The giant prolactin macroadenomas are generally compress if their treatment is very difficult. The surgical treatment is disappointing and is generally resistant to Bromocriptine.
Patients: 05 Patients (male) hospitalized for giant prolactin macroadenoma >to 04 cm (47 cm). 4/5 had less than 35 years (2449 years) they had an intracranial tumoral syndrome, a deterioration of vision and visual field (oedema - optical atrophy blindness). Prolactin was higher than 500 ng/ml (500>10 000 ng/ml). 02 patients were operated by rhinoseptale way. All the patients were treated by only Bromocriptine (2550 mg/j) initially then associated with Cabergoline (1 mg3,5 mg/Week).
Results: After 06 months, prolactin A decreases with less than 100 ng/ml. All the patients had a reduction of the size of the tumor at least 20% after 01 year. Ophthalmologic deteriorations remained stable with an improvement among 02 patients.
Discussion/Conclusion: Cabergoline is 30 times more effective than Bromocriptine, it is generally indicated during prolactin microadenoma little evaluated in the macroadenoma. Some studies brought back the effectiveness of the association of the bromocriptine and the cabergoline during giant prolactin macroadenoma.
Our modest study confirmed these results. This synergistic association can be a therapeutic alternative in this kind of pathology but a more significant number of patients must be evaluated.